|
Geron CorporationPublished by: SGA Lists Published: Oct. 1, 2009 - 2 Pages Table of Contents
AbstractGeron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||